Literature DB >> 17575071

OX40 costimulation turns off Foxp3+ Tregs.

Minh Diem Vu1, Xiang Xiao, Wenda Gao, Nicolas Degauque, Ming Chen, Alexander Kroemer, Nigel Killeen, Naoto Ishii, Xian Chang Li.   

Abstract

OX40 is a recently identified T-cell costimulatory molecule that belongs to the TNF/TNFR superfamily. OX40 can be expressed by both activated T effector cells and Foxp3(+) Tregs. It is well known that OX40 delivers a potent costimulatory signal to T effector cells, but very little is known about the role of OX40 in regulating the suppressor properties of Foxp3(+) Tregs and the de novo generation of new inducible Foxp3(+) Tregs from T effector cells. In the present study, we found, by using a newly created foxp3gfp knockin model, that OX40 was dispensable for the genesis and suppressor functions of naturally arising CD4(+)Foxp3(+) Tregs, but stimulating OX40 on the Foxp3(+) Tregs abrogated their ability to suppress T effector cell proliferation, IFN-gamma production, and T effector cell-mediated allograft rejection. OX40 costimulation did not significantly affect proliferation and survival of the naturally arising Foxp3(+) Tregs, but profoundly inhibited Foxp3 gene expression. Importantly, OX40 costimulation to T effector cells prevented the induction of new inducible Foxp3(+) Tregs from T effector cells. Our study identified OX40 as a key negative regulator of Foxp3(+) Tregs and may have important clinical implications in models of transplantation and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575071      PMCID: PMC1988917          DOI: 10.1182/blood-2007-01-070748

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  IL-15 and IL-2: a matter of life and death for T cells in vivo.

Authors:  X C Li; G Demirci; S Ferrari-Lacraz; C Groves; A Coyle; T R Malek; T B Strom
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

2.  Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression.

Authors:  Z X Zhang; L Yang; K J Young; B DuTemple; L Zhang
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

3.  Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.

Authors:  A I Chen; A J McAdam; J E Buhlmann; S Scott; M L Lupher; E A Greenfield; P R Baum; W C Fanslow; D M Calderhead; G J Freeman; A H Sharpe
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

4.  Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation.

Authors:  N Tsukada; H Akiba; T Kobata; Y Aizawa; H Yagita; K Okumura
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

5.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

6.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.

Authors:  Jeong M Kim; Jeffrey P Rasmussen; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2006-11-30       Impact factor: 25.606

7.  Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells.

Authors:  F Luhder; C Chambers; J P Allison; C Benoist; D Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

8.  Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells.

Authors:  Luis Graca; Alain Le Moine; Chun-Yen Lin; Paul J Fairchild; Stephen P Cobbold; Herman Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-24       Impact factor: 11.205

Review 9.  Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells.

Authors:  P Lane
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

10.  Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40.

Authors:  A G Jember; R Zuberi; F T Liu; M Croft
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  185 in total

1.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

Review 3.  An update on regulatory T cells in transplant tolerance and rejection.

Authors:  Xian Chang Li; Laurence A Turka
Journal:  Nat Rev Nephrol       Date:  2010-08-03       Impact factor: 28.314

4.  GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms.

Authors:  Palash Bhattacharya; Anupama Gopisetty; Balaji B Ganesh; Jian Rong Sheng; Bellur S Prabhakar
Journal:  J Leukoc Biol       Date:  2010-11-02       Impact factor: 4.962

Review 5.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

Review 6.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

Review 7.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

8.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

9.  TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury.

Authors:  Peixiang Lan; Yihui Fan; Yue Zhao; Xiaohua Lou; Howard P Monsour; Xiaolong Zhang; Yongwon Choi; Yaling Dou; Naoto Ishii; Rafik M Ghobrial; Xiang Xiao; Xian Chang Li
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

10.  Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Authors:  Michael D Oberst; Catherine Augé; Chad Morris; Stacy Kentner; Kathy Mulgrew; Kelly McGlinchey; James Hair; Shino Hanabuchi; Qun Du; Melissa Damschroder; Hui Feng; Steven Eck; Nicholas Buss; Lolke de Haan; Andrew J Pierce; Haesun Park; Andrew Sylwester; Michael K Axthelm; Louis Picker; Nicholas P Morris; Andrew Weinberg; Scott A Hammond
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.